Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

Not Applicable

• Conditions: Age Related Macular Degeneration

• Registration Number: NCT01626339
• Lead Sponsor: University of Malaya

Brief Summary

Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE).

Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye

Detailed Description

Not available

Study Timeline

• Study Start: 2012-04
• Status Verified: 2012-06
• Primary Completion: 2012-06
• Study First Submitted: 2012-06-20
• Study First Submitted QC: 2012-06-21
• Last Update Submitted: 2012-06-21
• Study First Posted: 2012-06-22
• Last Update Posted: 2012-06-22

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Patients who wish and need bevacizumab or ranibizumab treatment for underlying disease

Exclusion Criteria

• History of previous systemic or ocular Anti-VEGF therapy
• History of previous intravitreal injection with any drug
• Intraocular pressure ≥ 22
• Glaucoma
• History or presence of thromboembolic events
• Un-controlled blood pressure
• Blood donation during the previous 3 weeks
• Relevant media opacity of the lens

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

University of Malaya Medical Center; 🇲🇾 Kuala Lumpur, Malaysia